09/24/03 SageGroup Strategies Announces Major Financing Program for HMS and Other Quality Medical Technology Companies

Boston, MA; New York, NY; and Alameda, CA - September 24, 2003 - SageGroup Strategies, Inc., announces that it has implemented a major national and international Medical Industries Financing Program emphasizing quality medical technology companies.

The Program encompasses a large variety of appropriate types of equity and debt financing for such medical companies during their life cycles of start-up, rapid growth, maturity, sale, and other potential cycle stages. The potential financing sources are very many, just some of which are: angel investors, venture capitalists, active management team involvees, asset-based lenders, investment bankers, commercial bankers, governmental entities, entrepreneurs, IPOs and other public offerings, other medical technology or otherwise complementary companies, and various others.

A major current priority is the financing of HMS, a very attractive medical technology company with excellent technology, products, management team, customer base, and other impressive aspects. The HMS Financing Program is being managed by the strong HMS Financing Council, whose members are Randy Friedman, Manny Kyriannis, Larry Lindsey, Greg Smith, Peter Welch, and Paul Wilde.

Below is a very new September 23 HMS Financing Sheet regarding HMS and the types of financing sources that it is currently seeking. As the Sheet indicates, additional information is available at once, preferrably by contacting Randy Friedman or Larry Lindsey at 510-8652480.

Also, more broadly, SGS is seeking working relationships with many more financing entities of the various types mentioned above. Such relationships can relate not only to client referrals in both directions but also potentially to SGS providing free marketing for the other firms and/or SGS opening local SGS Offices. Additional information on this is available from Larry Lindsey at 510-8652480.

MEDIA CONTACT:
David Lawrence
SageGroup Strategies, Inc.
International Coordination Office
1370 Third Street, Suite 110
Alameda, CA 94501
http://www.SageGroupStrategies.com
SGS@SageGroupStrategies.com
(510) 865-2480

HMS SEARCH FOR FINANCING SOURCES

September 23, 2003

To Selected SGS Associates and Appropriate Others:

Haynes Medical Systems, Inc. (HMS) is an innovative international medical technologies company that was organized specifically to take advantage of a wide array of opportunities in the medical technologies sector. HMS is seeking financing for operations and further expansion. Please help the HMS management team identify and gain an introduction to sources of financing that are likely to be attracted to this opportunity. Some appropriate financing sources for HMS at this time include angel investors, venture capitalists, medical and other technology companies, plus professionals potentially interested in joining HMS's management team. There are excellent financial and other incentives offered to those successful in these efforts. Here are some of the basic facts:

1. HMS was founded in August 2003 as a larger, stronger, management-team-run successor to a well-established medical technology manufacturing company specializing in niche radiation oncology diagnostic equipment used in treatment protocols for cancer. From this company, HMS acquired the exclusive and worldwide marketing and product rights for this innovative radiation oncology technology and products, including the RAD II.

2. HMS's RAD II is a therapy attached diagnostic solution which operates in tandem with Medical Linear Accelerators for improved Intensity Modulated Radiation Therapy, or IMRT. The RAD II application improves IMRT applications offered through leading manufacturers such as: Varian Medical Systems, GE Medical, Siemens Medical Systems, and other global vendors. The RAD II application is used in both "Simulation" and "Verification" phases of radiation therapy treatments. By analogy, if one likens the linear accelerator to a radiation cannon, the RAD II is an attached "gun sight, or radar" which sets up or verifies the target aiming for improved accuracy during "beam-on" firing of the cannon.

3. With the RAD II, HMS is the only provider of this "Therapy Attached three-dimensional imaging" capability in the world. Unlike two-dimensional attached systems starting to be offered by some therapy manufacturers, the Dual Headed RAD II represents a new generation of attached diagnostic solutions capable of delivering three-dimensional digital imaging for "real-time" verification and field adjustments for IMRT protocols right on the therapy machine before and during treatment. Two world-class research hospitals - one in Japan and the other in the Northeastern USA - are now deploying the Dual Headed RAD II application.

4. HMS has a very strong management team with many years of industry and/or functional experience and will add executives, when and as needed, to enhance its organization and strategic position. This professional team has the education, technical experience, capabilities, and knowledge required in the areas of executive management, finance and financing, marketing and sales, operations, computer systems, corporate development, global sourcing, international business, trade/barter, accounting, administration, and other functional areas.

5. Business, Medical, and Technology Advisory Boards have been created to provide the Company with professional input and advice on: medical marketplace aspects and evolutions; acquisitions and other corporate development transactions; long-term strategic and business plans; new products and other technological advancements; and other business, medical, and technological priorities and opportunities as appropriate.

6. HMS has also identified several other medical technology companies as potential acquisition targets, strategic allies, or companies from which HMS may acquire exclusive worldwide marketing and product rights for products that are compatible with highly-specialized radiation oncology applications worldwide. HMS is structured and organized to professionally market, sell, and service a wide array of medical technology equipment and other products worldwide.

In order to ensure that HMS is well-financed at all times, HMS has established an on-going financing program to acquire the appropriate blend of debt, equity, and other forms of financing. Financing will be arranged on a step-by-step incremental basis. It is anticipated that the Company's total and per-share market values will increase rapidly, thus allowing for attractive financial returns and for a variety of potential exit strategies for the stockholders.

Please contact Larry Lindsey or me at 510-8652480 with any questions, information requests, etc. Thank You.

Sincerely,

Randy Friedman